Yeah i can understand that you can't project success from PFS but surely if the patient has their cancer return earlier than an already approved drug then you can safely say that the drug is likely to elicit inferior OS?
And conversely, say a 30% improvement on PFS would be a fairly robust indicator of superiority?
I'd certainly trade based on that information if that's all we have to go on.
I daresay the market will do the same.
Understanding Telix, page-715
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7316 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.13 | 6814 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |